Tisch Multiple Sclerosis Research Center Of New York Inc is located in New York, NY. The organization was established in 2015. According to its NTEE Classification (H48) the organization is classified as: Brain Disorders Research, under the broad grouping of Medical Research and related organizations. As of 12/2021, Tisch Multiple Sclerosis Research Center Of New York Inc employed 47 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Tisch Multiple Sclerosis Research Center Of New York Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Tisch Multiple Sclerosis Research Center Of New York Inc generated $12.6m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 5.7% each year. All expenses for the organization totaled $9.9m during the year ending 12/2021. While expenses have increased by 4.4% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
THE PURPOSE OF TISCH MULTIPLE SCLEROSIS RESEARCH CENTER OF NY, INC. IS TO CONDUCT MEDICAL RESEARCH DIRECTED TOWARD FINDING THE CAUSE AND EVENTUAL CURE FOR MULTIPLE SCLEROSIS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
TISCH MS RESEARCH CENTER OF NEW YORK'S (TISCH MSRCNY) MISSION IS TO CONDUCT MEDICAL RESEARCH DIRECTED TOWARD DISCOVERING THE CAUSE OF AND EVENTUAL CURE FOR MULTIPLE SCLEROSIS. IN 2021, ADVANCEMENTS WERE MADE IN THE STEM CELL RESEARCH PROGRAM. DRS HARRIS AND SADIQ CONDUCTED A LONG TERM FOLLOW UP STUDY OF MS PATIENTS IN THE PHASE I CLINICAL TRIAL, WHICH WAS PUBLISHED IN THE JOURNAL NEUROLOGY NEUROIMMUNOLOGY AND NEUROINFLAMMATION. THE PHASE II CLINICAL TRIAL OF STEM CELL IN MS WAS FULLY ENROLLED WITH NO SERIOUS ADVERSE EVENTS RELATED TO THE TREATMENT. CLINICAL TRIAL RESULTS ARE EXPECTED IN 2023. IN ADDITION, TISCH MSRCNY RESEARCHERS WERE INVITED TO PRESENT RESEARCH ABSTRACTS AT ANNUAL CONFERENCES OF THE AMERICAN ACADEMY OF NEUROLOGY, THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH AND THE SOCIETY FOR NEUROSCIENCE, ALL HELD VIRTUALLY IN 2021. IN 2021, TISCH MSRCNY CONTINUED CONSTRUCTION ON A NEW FACILITY, THE EXPERIMENTAL RESEARCH CENTER, AN EXPANSION OF THE EXISTING LABORATORIES. THIS PROJECT IS EXPECTED TO BE COMPLETED BY FALL OF 2022.
AS AN ACADEMIC FACILITY, THE TISCH MS RESEARCH CENTER PROVIDES EDUCATIONAL AND TRAINING RESOURCES FOR MS RESEARCHERS AND MEDICAL PROFESSIONALS. ONE OF THE MOST IMPORTANT GOALS OF TISCH MSRCNY IS TO PROVIDE RESEARCH OPPORTUNITIES FOR YOUNG SCIENCE GRADUATES THAT ENABLE THEM TO BECOME CAREER SCIENTISTS. SINCE ITS INCEPTION, THEY HAVE TRAINED OVER 100 COLLEGE GRADUATES AS RESEARCH ASSISTANTS (RAS) FOR 2-YEAR ROTATIONS. IN 2021, ALL SECOND YEAR RESEARCH ASSISTANTS, UNDER THE GUIDANCE OF TISCH MSRCNY PRINCIPAL INVESTIGATORS, MATRICULATED TO TOP MEDICAL SCHOOLS AND GRADUATE PROGRAMS. FELLOWSHIPS IN MS RESEARCH ARE ALSO OFFERED TO PHYSICIANS AND SCIENTISTS INTERESTED IN ENTERING OR EXPANDING THEIR WORK IN THIS FIELD. WEEKLY JOURNAL CLUB MEETINGS OR GRAND ROUNDS TAKE PLACE IN OUR CONFERENCE ROOM OR VIRTUALLY TO DISCUSS THE LATEST ADVANCEMENTS IN MS RESEARCH AND HOW IT APPLIES TO OUR CURRENT INVESTIGATIONS. THESE RESEARCH INITIATIVES INCLUDE: TO BETTER UNDERSTAND AND TREAT COORDINATION AND BALANCE DIFFICULTIES IN PATIENTS WITH MS. TO CREATE AN EXPERIMENTAL MODEL OF PROGRESSIVE MS THAT WILL ENABLE US TO BETTER UNDERSTAND AND TREAT PATIENTS WITH SECONDARY PROGRESSIVE MS (SPMS) AND PRIMARY PROGRESSIVE MS (PPMS). TO UTILIZE NOVEL CEREBROSPINAL FLUID BASED ANIMAL MODELS TO BETTER UNDERSTAND OTHER NEURODEGENERATIVE DISEASES SUCH AS ALS TO DEVELOP ORGANOID MODELS TO BETTER UNDERSTAND THE UNDERPINNINGS OF PROGRESSIVE MS FINALLY, AND PERHAPS MOST IMPORTANTLY, WE NEED TO IDENTIFY THE INTITIAL TRIGGER(S) THAT CAUSE MS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Violaine Harris Senior Research Scientist | 40 | $195,926 | |
Amanda B Oppenheimer Chief Operating Officer | Officer | 40 | $170,707 |
Jerry Lin Senior Staff Associate | 40 | $123,534 | |
Jamie Wong Research Scientist | 40 | $112,135 | |
Qijiang Yan Research Scientist | 40 | $101,123 | |
Philip Weisberg Chairman | OfficerTrustee | 15 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Trademark Mechanical Hvac Installation | 12/30/21 | $2,047,493 |
Denmar Electric Corp Electrical Installation | 12/30/21 | $293,210 |
Conroy Construction General Contracting | 12/30/21 | $303,252 |
Abm Systems Inc Mechanical Services | 12/30/21 | $448,750 |
Stephen Foy Mechanical Service Corp Mechanical Services | 12/30/21 | $627,707 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $2,768,420 |
Related organizations | $0 |
Government grants | $574,695 |
All other contributions, gifts, grants, and similar amounts not included above | $9,281,826 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $12,624,941 |
Total Program Service Revenue | $0 |
Investment income | $1,227 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | -$4,875 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $12,621,293 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $2,470,451 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $825,965 |
Payroll taxes | $229,609 |
Fees for services: Management | $28,626 |
Fees for services: Legal | $10,274 |
Fees for services: Accounting | $29,169 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $0 |
Advertising and promotion | $0 |
Office expenses | $162,690 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $3,113,178 |
Travel | $0 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $5,510 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $551,312 |
Insurance | $103,876 |
All other expenses | $0 |
Total functional expenses | $9,924,324 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $1,056,415 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $361,420 |
Net Land, buildings, and equipment | $12,662,145 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $39,750 |
Total assets | $14,119,730 |
Accounts payable and accrued expenses | $516,746 |
Grants payable | $0 |
Deferred revenue | $162,000 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $239,622 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $474,386 |
Total liabilities | $1,392,754 |
Net assets without donor restrictions | $8,448,434 |
Net assets with donor restrictions | $4,278,542 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $14,119,730 |
Over the last fiscal year, we have identified 26 grants that Tisch Multiple Sclerosis Research Center Of New York Inc has recieved totaling $2,729,505.
Awarding Organization | Amount |
---|---|
Jewish Communal Fund New York, NY PURPOSE: GENERAL SUPPORT | $1,627,536 |
Moccasin Lake Foundation wilmington, DE PURPOSE: GENERAL & UNRESTRICTED | $450,000 |
Schwab Charitable Fund San Francisco, CA PURPOSE: HEALTH | $315,900 |
Goldman Sachs Philanthropy Fund New York, NY PURPOSE: MEDICAL / PUBLIC SERVICES | $105,000 |
Harry F Mariani Family Foundation Locust Valley, NY PURPOSE: GENERAL SUPPORT | $50,000 |
American Endowment Foundation Hudson, OH PURPOSE: MEDICAL RESEARCH | $38,000 |
Organization Name | Assets | Revenue |
---|---|---|
The International Academy Of Hope New York, NY | $21,778,473 | $17,024,094 |
Tisch Multiple Sclerosis Research Center Of New York Inc New York, NY | $14,119,730 | $12,621,293 |
Apbd Research Foundation Brooklyn, NY | $480,862 | $398,154 |
Ibrea Foundation New York, NY | $1,239,920 | $344,213 |
Mind Your Brain Berwyn, PA | $206,976 | $300,317 |
Bounce Out The Stigma Project Inc Allendale, NJ | $44,213 | $0 |
Pierce Family Fragile X Foundation Inc Winchester, MA | $47,634 | $0 |
Charles Maddock Foundation New York, NY | $0 | $391 |
Neuronetworks Fund Inc New Canaan, CT | $156,501 | $0 |
Irene & Eric Simon Brain Research Foundation Inc Sparta, NJ | $310,495 | $0 |
Bryces Bridge Of Hope Thorofare, NJ | $6,277 | $26 |
Brain Injury Foundation Merion Station, PA | $3,870 | $280 |